Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3085 SEK | -4.19% | -13.22% | -96.92% |
May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.92% | 46.73M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB - Special Call